Please amend the claims as follows:

Claims 1-19 **(Canceled)**

Newly presented claims are as follows:

20. **(NEW)** A high melting polymorphic form of (+)-(S)-clopidogrel bisulfate Form-I.
21. **(NEW)** The Form-I of clopidogrel bisulfate of claim 20, wherein the clopidogrel has a melting point of 198°C to 200 °C.
22. **(NEW)** The Form-I of clopidogrel bisulfate of claim 20, wherein the clopidogrel has a purity of more than 99% by HPLC.
23. **(NEW)** The Form-I of clopidogrel bisulfate of claim 22, wherein the clopidogrel has a purity of more than 99.96%.
24. **(NEW)** The Form-I of clopidogrel bisulfate of claim 20, wherein the clopidogrel has a particle size (d 0.9) of from about 62 to about 426 microns.
25. **(NEW)** Pure (+)-(S)-clopidogrel bisulfate Form-I having a purity of more than 99 %.
26. **(NEW)** The pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25, wherein the clopidogrel has a purity of more than 99.96 %.
27. **(NEW)** The pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25, wherein the clopidogrel has a melting point 198 to 200 °C.
28. **(NEW)** The pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25, wherein the clopidogrel has a particle size (d 0.9) from about 62 to about 426 microns.
29. **(NEW)** A pharmaceutical composition comprising a high melting polymorphic form of (+)-(S)-clopidogrel bisulfate Form-I.

30. **(NEW)** A pharmaceutical composition comprising the pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25.

31. **(NEW)** A process for the preparation of (+)-(S)-clopidogrel bisulfate Form-I, the process comprising:

a) dissolving (+)-(S)-clopidogrel in an ester solvent;

b) adding sulfuric acid; and

c) isolating (+)-(S)-clopidogrel bisulfate Form-I.

32. **(NEW)** The process of claim 31 further comprising drying of the product obtained.

33. **(NEW)** The process of claim 31, wherein the solvent is ethyl acetate.

34. **(NEW)** The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a melting point of 198°C to 200 °C.

35. **(NEW)** The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a purity of more than 99% by HPLC.

36. **(NEW)** The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a purity of more than 99.96% by HPLC.

37. **(NEW)** The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a particle size (d 0.9) from about 62 to about 426 microns.

38. **(NEW)** A process for the preparation of pure (+)-(S)-clopidogrel bisulfate Form-I having a purity of more than 99 %, the process comprising:

a) dissolving (+)-(S)-clopidogrel in an ester solvent;

b) adding sulfuric acid; and

c) isolating the pure (+)-(S)-clopidogrel bisulfate Form-I having a purity of more than 99%.

39. **(NEW)** The process of claim 38, wherein the solvent is ethyl acetate.

40. **(NEW)** The process of claim 38, wherein the Form-I of clopidogrel bisulfate has a melting point of 198°C to 200 °C.